2025年1月22日 · Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant...

2023年11月12日 · Abelacimab is an injectable, monoclonal antibody, categorized as a factor XI inhibitor, that has the potential to prevent the clots that cause strokes and heart attacks while preserving the body’s natural ability to repair blood vessels during an injury.

2023年11月17日 · Abelacimab is an injectable, experimental, anti-clotting medication that is categorized as a factor XI inhibitor. It has the potential to prevent the clots responsible for strokes and heart attacks while preserving the body's natural ability to repair blood vessels after an injury.

2021年7月19日 · Abelacimab (MAA868) is a fully human monoclonal antibody that binds to the catalytic domain of factor XI and locks it in the zymogen (inactive precursor) conformation, thereby preventing its ...

Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis, [1] under development by Anthos Therapeutics. It is anti-factor XI antibody.

2025年1月22日 · Abelacimab shows a 62% reduction in major or clinically relevant non-major bleeding compared to rivaroxaban in AFib patients. The study highlights an 89% reduction in gastrointestinal...

Abelacimab, an antibody that inhibits FXI, has shown potential in transforming anticoagulation therapy by sparing hemostasis. This review provides a comprehensive analysis of abelacimab, examining its clinical pharmacology and its pharmacokinetic and pharmacodynamic properties.

2024年8月15日 · In the ASTER trial, Anthos’ novel dual-acting Factor XI monoclonal antibody, abelacimab, is being compared to apixaban, the leading Factor Xa inhibitor, to assess their effects on venous thromboembolism (VTE) recurrence and bleeding in …

Abelacimab is a monoclonal antibody that inhibits Factor XI and the activated Factor XI (FXIa). The pharmacokinetics of abelacimab were studied in healthy subjects and patients with atrial fibrillation. Abelacimab IV/SC was well‐tolerated and profoundly suppressed FXI for 4 weeks.

2025年2月11日 · Abelacimab showed a 60-70% reduction in bleeding events compared to rivaroxaban, leading to early trial termination.